Skip to content
    CLPT
    Earnings call· Jun 2026(Q2 FY26)

    ClearPoint Neuro Q2 FY26 earnings call CLPT

    Aug 3, 2026 Source

    Executive summary

    ClearPoint Neuro Q2 FY26 — Strategic Reprioritization Towards Commercial Readiness and CAL Expansion

    ClearPoint Neuro is strategically reprioritizing its investments in Q2 FY26, shifting focus from traditional sales expansion to clinical support for commercial drug delivery, global regulatory product expansion, and development of its CAL facility and robotic/Harmony software. This pivot is driven by accelerated FDA pathways for gene therapies and the new 30,000 sq ft CAL facility, positioning the company for future commercial scale and efficiency in neuro drug delivery. The company aims to avoid being a bottleneck for upcoming commercial launches by scaling its clinical support and infrastructure.

    Highlights

    5

    • Total revenue grew 18% to $10.9 million in Q2 FY26.

    • Neurosurgery navigation revenue grew to $5.6 million in Q2 FY26, driven by Aeroflow and 3.0 software.

    • Gross margin increased to 62% in Q2 FY26, up 2% compared to Q2 FY25.

    • First GLP services statement of work signed for the new 30,000 sq ft CAL facility, expected to complete in H1 2027.

    • FDA regulatory updates indicate accelerated pathways for gene therapy approvals, leading to strategic reprioritization for commercial readiness.

    Concerns

    6

    • Biologic drug delivery revenue decreased 15% to $4 million in Q2 FY26, primarily due to a non-recurring customer order in the prior year.

    • R&D costs increased 21% to $4.6 million in Q2 FY26.

    • Sales and marketing expenses increased 68% to $6.8 million in Q2 FY26.

    • General and administrative expenses increased 64% to $5.6 million in Q2 FY26.

    • Operational cash burn was $15 million through Q2 FY26.

    • 2026 revenue guidance adjusted to $48-$52 million, reflecting a shift from traditional sales expansion.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $48M-$52M
    high materiality
    High
    Operational Cash Burn
    decrease
    medium materiality
    High
    2027 Total Revenue Growth
    high teens, 20%+
    high materiality
    Medium
    GLP Services SOW Completion
    complete in the first half of 2027
    medium materiality
    High
    Clinical Specialist Team Readiness
    12 to 15 months to get ready
    medium materiality
    High
    Trials using ClearPoint technology
    between 10 and 15 trials enrolling patients
    medium materiality
    High
    CAL Facility Equipment Installation
    permanent installation of our MRI magnets and spec machines take place in the first quarter of next year
    medium materiality
    High
    Robotic Devices for Preclinical Use
    fully functioning devices to be used pre-clinically at the CALS facility
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Total Revenue
    Total revenue for the three months ended June 30, 2026, compared to $9.2 million for the same period in 2025.
    		$10.9M18%——
    Biologic Drug Delivery
    Includes sales of disposable products and services related to customer sponsored preclinical and clinical trials. Decrease mainly due to a single customer order in Q2 2025 that did not recur.
    Product revenue decrease: $0.9M (due to non-recurring prior year order)Service revenue increase: $0.2M
    		$4M-15%——
    Neurosurgery Navigation Therapy
    Consists of commercial sales of disposable products related to cases utilizing the ClearPoint system, PRISM laser system, and Aeroflow. Growth driven primarily by additional revenues from Aeroflow product sales and 3.0 operating room navigation software.
    		$5.6M———
    Capital Equipment and Software
    Consisting of sales of reusable hardware and software and related services. Increased from $1 million in Q2 2025 due to increased placement of ClearPoint navigation systems, PRISM laser units, and Aeroflow control units.
    		$1.3M24%——

    Operational metrics

    13
    Gross Margin
    62%up 2% vs Q2 FY25
    Q2 FY26

    Increase mostly related to a decrease in excess and obsolete inventory.

    Research and Development Costs
    $4.6Mup $0.8M (21%) vs Q2 FY25
    Q2 FY26

    Increase primarily due to higher personnel costs of $0.8 million.

    Sales and Marketing Expenses
    $6.8Mup $2.7M (68%) vs Q2 FY25
    Q2 FY26

    Increase due to expansion of clinical and sales teams.

    General and Administrative Expenses
    $5.6Mup $2.2M (64%) vs Q2 FY25
    Q2 FY26

    Increase due to various operational and corporate costs.

    Operational Cash Burn
    $15M
    through Q2 FY26

    Cash reduction primarily due to operational cash burn. Expected to decrease in H2 FY26.

    Aeroflow Revenue
    $2.45M
    Q2 FY26

    Breakout of Aeroflow product contribution to revenue.

    Revenue per Unicure Procedure
    $15,000-$25,000
    per procedure

    Estimated revenue generated from a typical Unicure procedure, based on navigation and cannula sales.

    Revenue per Patient (Internal Model)
    $12,000-$15,000
    per patient

    Internal modeling estimate for revenue generated per patient across all pharma partners.

    CAL Facility Prior Annual Capacity
    $8M
    annual

    Prior preclinical capacity at the old facility.

    CAL Facility New Annual Capacity
    >$60M
    annual

    Projected annual capacity at the new 30,000 sq ft CAL facility with GLP and additional services.

    Clinical Specialists
    30-40+
    current

    Number of trained clinical specialists capable of basic navigation cases, with ongoing training for new hires.

    Clear Trial Program Qualified Centers
    15
    first couple months

    Number of centers that have completed site readiness assessment and committed to 1-2 procedures per week.

    GLP Services Statement of Work Value
    multi-million dollar range
    first SOW

    Total value of the first GLP services contract signed for the CAL facility, split into multiple parts.

    Industry KPIs

    4
    MetricValueDetails
    Procedure volume growthpositively impacted
    Installed base system placementsincreased
    Segment franchise organic growth18%%
    Sales force commercial capacity buildhiring

    Deals & partnerships

    2
    Focused Ultrasound partnerDevelopment and commercialization of focused ultrasound technology10-year

    Partnership to combine focused ultrasound with ClearPoint's robotic system and Harmony 1.0 software to assist in drug delivery growth and commercial expansion.

    UCBAcquisition of Neurona Therapeutics

    UCB acquired Neurona Therapeutics, a ClearPoint partner, which had presented updated Phase 1-2 data in drug resistant mesial temporal lobe epilepsy.

    Risks & headwinds

    4
    Biologic drug delivery revenue declineQ2 FY26

    $0.9M decrease in product revenue

    Mitigation: Decrease attributed to a non-recurring customer order in the prior year; service revenue increased $0.2M.

    Delayed ramp of preclinical CAL servicesQ2 FY26

    Impacted Q2 revenue miss vs. internal plan

    Mitigation: Due to pharma partners' comfort with studies in a live construction zone; facility now in possession as of July, expecting return to growth in H2 2026.

    Operational cash burnthrough Q2 FY26

    $15M through Q2 FY26

    Mitigation: Expected to decrease in H2 FY26 as the company benefits from the completion of ERAS integration.

    Investment focus shiftFY26

    2026 revenue guidance adjusted to $48M-$52M

    Mitigation: Investment is less focused on traditional sales expansion and more on clinical case support for commercial drug delivery, global regulatory product expansion, capital equipment, and development of new software solutions.

    What to watch in Q3 FY26

    5

    2026 Revenue Guidance

    next quarter
    Current$48M-$52M
    TargetReaffirmation or revision of guidance

    Why it matters

    Indicates overall business trajectory and impact of strategic reprioritization.

    As a result of these new priorities and investments, we are adjusting our 2026 revenue guidance to between 48 and $52 million, as our investment will be less focused on traditional sales expansion than previously planned and more focused on clinical case support for commercial drug delivery, global regulatory product expansion, capital equipment, equipment purchases at the Cal and development of our focused ultrasound robotics and harmony software solutions.

    Q&A highlights

    9

    Can you elaborate on the strategic reorganization, specifically regarding sales reps moving to clinical support, and how this impacts 2027 growth?

    Management explained the shift towards clinical support roles due to the unique B2B model with pharma partners, where products are kitted with drugs. This requires a different type of salesperson focused on clinical support for high-value procedures. They projected high teens to 20% growth for 2027, with potential acceleration from CAL GLP studies and commercial approvals leading to stocking orders.

    “it's not a massive change to what we had originally planned, but it is a reflection on, you know, what does the company and the commercial team need to look like, you know, two, three years out in the future? You know, the reality is is that our company and our business model is very different than a traditional device company.”

    asked by Frank Pekkanen, Lake Street Capital Market · answered by Joseph Burnett

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Reprioritization

    ClearPoint Neuro is adapting its four-pillar growth strategy in response to recent market developments, focusing on three elevated priorities for the second half of 2026. These include preparing for accelerated regulatory pathways for gene therapies, operationalizing the new CAL facility, and advancing technology for commercial drug delivery scale. This shift represents the largest time and financial investment for the remainder of the year, moving away from traditional sales expansion towards clinical support and infrastructure build-out.

    02

    Accelerated Regulatory Pathways and Commercial Readiness

    Recent FDA updates indicate a potentially accelerated pathway for rare disease gene therapies, with BLA submissions possible as early as H2 2026. This has prompted ClearPoint to reactivate its clinical support growth strategy, investing in global clinical specialist teams across the US, EU, Canada, and Japan. The goal is to ensure ClearPoint's technology and clinical team are not bottlenecks for upcoming phase three trials and commercial launches, with 10-15 trials expected to enroll patients in the next 18 months.

    03

    CAL Facility Operationalization and Growth

    The company has taken possession of its new 30,000 sq ft ClearPoint Advanced Laboratories (CAL) facility in Torrey Pines, California. This milestone enabled the signing of the first multi-million dollar statement of work for GLP services, expected to complete in H1 2027. The CAL is projected to significantly expand preclinical service capacity from $8 million to over $60 million annually, offering increased study capacity, GLP-compliant services, and new capabilities like histology. While Q2 revenue was impacted by a delayed ramp, growth is expected to return in H2 2026.

    04

    Advancing Technology for Commercial Scale

    ClearPoint is developing a robotic system and Harmony 1.0 control software, alongside a focused ultrasound partnership, to support partners in achieving commercial drug delivery scale. These technologies are designed to increase access and efficiency of robotic workflows and enable intravenously administered agents to cross the blood-brain barrier. The robotic platform is specifically designed for cranial procedures, differentiating it from competitors whose systems are 95% focused on spine procedures. Fully functioning preclinical devices are expected in 2027.

    05

    Biopharma Partner Pipeline Progress

    Significant progress was reported across ClearPoint's biopharma partners. Unicure's AMT-130 for Huntington's disease is targeting Q3 BLA submission via an accelerated approval pathway. Aspen Neuroscience received RMAT designation for Parkinson's and completed dosing for cohorts 3 and 4. Kenai Therapeutics completed enrollment for its Parkinson's trial. Neurona Therapeutics presented positive epilepsy data and was acquired by UCB. SIREN Biotechnology received an $8 million grant for high-grade gliomas, and Regenexx Bio expects Q3 BLA resubmission for MPS2 after FDA alignment.

    AI-generated summary of the company’s earnings call. Not investment advice.